The Active Pharmaceuti- cal Ingredients (API) market in South East Asia is entering a criti- cal phase of evolution. Once viewed primarily as a consumer market for finished pharmaceu- tical products, the region is now positioning itself as an emerg- ing hub for API sourcing, manu- facturing scale-up, and contract development and manufac- turing (CDMO) services.